NR5A2 and central nervous system cancer: In a study by Yang et al.,14 NR5A2 was expressed at high levels in glioma tissues, and the overexpression of NR5A2 in temozolomide (TMZ)‐resistant glioma cells increased their resistance to the drug while the knockdown of NR5A2 reduced their resistance to the drug.